11/12/2017
SUS incorporates Pertuzumab in the treatment of HER2-positive breast cancer
In these difficult days for the country and for public health, EXCELLENT NEWS: the incorporation, by the SUS, of PERTUZUMAB for the treatment of patients with HER2-positive metastatic breast cancer. This represents More LIVES with more QUALITY!!!
See the ordinance that makes the matter official: